Kathie P Huang, MD
Dermatology · Boston
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Brigham and Womens Physicians Organization Inc · 2,931 clinicians in this group
Looking this up.
Hospitals listed: Brigham and Women'S Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Huang’s office at (617) 732-5500 to ask if they take your plan before you enroll.
California Medical Board record
Licence A96417 · Cancelled
Licence status: Cancelled · since 2006 · Stanford University School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Brigham and Women'S HospitalBoston, MAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Mass General Brigham, which runs 15 hospitals in 2 statesHome of Dana-Farber/Harvard Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.711, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.596, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.505, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.51, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 0.9) · 2,432 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Brigham and Women'S Hospital
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.711 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.596 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.505 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.51 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 0.9) · 2,432 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.69 (0.12 to 1.26) · 6,008 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.74 to 1.01) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.29 (133.21 to 183.36) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 365 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.1 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.7 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 697 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.5 · 456 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 6,699 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0.01 to 0.29) · 21,284 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.13 to 0.42) · 24,178 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.49 (3.47 to 5.51) · 9,415 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.37 (1.52 to 3.21) · 5,676 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (1.23 to 2.88) · 8,589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.32 (5.06 to 9.58) · 5,122 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.49 (3.06 to 5.92) · 5,826 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.31 (0.19 to 2.43) · 2,520 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0.05 to 0.63) · 21,256 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 384 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.332 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.684 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 576 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 1,117 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 30 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.9 · 1,164 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 16.7 · 758 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 721 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3 to 7.2) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 7.5 (5.3 to 10.9) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 371 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.5 (9.5 to 14) · 5,029 cases | No different | Jan 2022 – Dec 2024 |
What patients said (666 patients answered, 23% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$47,163
Medicare paid this office $47,163 for 380 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 259 | $25,742 | $68 |
| Short return visit (20+ min) | 124 | $7,215 | $47 |
| Destruction of precancer skin growth, 1 growth | 117 | $6,013 | $41 |
| Destruction of skin growth, 1-14 growths | 35 | $2,296 | $57 |
| New patient visit (45+ min) | 18 | $1,727 | $96 |
See all 8 services
| Return visit (30+ min) | 259 | $25,742 | $68 |
| Short return visit (20+ min) | 124 | $7,215 | $47 |
| Destruction of precancer skin growth, 1 growth | 117 | $6,013 | $41 |
| Destruction of skin growth, 1-14 growths | 35 | $2,296 | $57 |
| New patient visit (45+ min) | 18 | $1,727 | $96 |
| Biopsy of related skin growth, first growth | 62 | $1,452 | $23 |
| New patient visit (30+ min) | 15 | $810 | $54 |
| Destruction of precancer skin growth, 2-14 growths | 69 | $421 | $2 |
Procedures Medicare counted
| Removal of skin lesions | 399 | More than 85% of doctors who do this |
| Skin biopsy | 122 | More than 78% of doctors who do this |
Who their Medicare patients are
380 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 6% · Women 83% · Also on Medicaid 9% · Health risk score 0.88. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 56% · Depression 22% · Cancer 18% · Diabetes 16% · Coronary heart disease 14% · Chronic kidney disease 10% · Atrial fibrillation 8% · COPD 7% · Stroke 5% · Heart failure 4%.
The office billed $289,870, Medicare allowed $68,248 and paid $47,163; for 1,126 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 380 | 1,126 | 74 | 0.88 | $289,870 | $47,163 |
| 2023 | 350 | 1,069 | 74 | 0.90 | $267,588 | $45,051 |
| 2022 | 345 | 1,069 | 73 | 0.90 | $260,781 | $47,238 |
| 2021 | 326 | 1,270 | 73 | 0.81 | $252,192 | $52,183 |
| 2020 | 282 | 923 | 72 | 0.97 | $173,524 | $30,439 |
| 2019 | 328 | 992 | 72 | 0.99 | $188,872 | $34,898 |
| 2018 | 300 | 1,105 | 73 | 0.95 | $196,170 | $36,429 |
| 2017 | 313 | 1,233 | 72 | 0.98 | $203,552 | $37,838 |
| 2016 | 250 | 926 | 73 | 1.06 | $142,375 | $24,949 |
| 2015 | 324 | 1,170 | 72 | 0.94 | $189,238 | $35,963 |
| 2014 | 288 | 1,197 | 72 | 0.98 | $180,538 | $34,811 |
| 2013 | 199 | 765 | 72 | 0.88 | $107,202 | $19,966 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 238 | $24,787 | $71 |
| Short return visit (20+ min) | 139 | $7,449 | $47 |
| Destruction of precancer skin growth, 1 growth | 99 | $5,252 | $41 |
| New patient visit (45+ min) | 19 | $1,759 | $93 |
| Destruction of skin growth, 1-14 growths | 31 | $1,756 | $52 |
| Biopsy of related skin growth, first growth | 51 | $1,324 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 75 | $412 | $2 |
| Biopsy of related skin growth, each additional growth | 12 | $296 | $18 |
2022: 10 services
| Return visit (30+ min) | 216 | $23,044 | $76 |
| Short return visit (20+ min) | 163 | $9,811 | $49 |
| Destruction of precancer skin growth, 1 growth | 92 | $4,867 | $41 |
| Destruction of skin growth, 1-14 growths | 46 | $3,092 | $52 |
| New patient visit (45+ min) | 22 | $2,427 | $110 |
| Biopsy of related skin growth, first growth | 43 | $1,063 | $23 |
| Injection into skin growth, 1-7 growths | 13 | $667 | $22 |
| Punch biopsy, first skin growth | 17 | $632 | $37 |
| Destruction of precancer skin growth, 2-14 growths | 62 | $382 | $2 |
| Biopsy of related skin growth, each additional growth | 12 | $248 | $19 |
2021: 12 services
| Return visit (30+ min) | 195 | $21,680 | $81 |
| Short return visit (20+ min) | 162 | $12,282 | $53 |
| Destruction of precancer skin growth, 1 growth | 106 | $5,947 | $42 |
| Destruction of skin growth, 1-14 growths | 50 | $3,571 | $58 |
| New patient visit (30+ min) | 24 | $1,676 | $70 |
| Biopsy of related skin growth, first growth | 63 | $1,566 | $23 |
| New patient visit (45+ min) | 11 | $1,307 | $119 |
| Injection into skin growth, 1-7 growths | 16 | $887 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 72 | $543 | $2 |
| Punch biopsy, first skin growth | 18 | $502 | $28 |
| Biopsy of related skin growth, each additional growth | 17 | $409 | $16 |
| Short return visit | 14 | $307 | $22 |
2020: 11 services
| Return visit (30+ min) | 189 | $12,474 | $57 |
| Short return visit (20+ min) | 116 | $5,826 | $38 |
| Destruction of precancer skin growth, 1 growth | 92 | $4,560 | $41 |
| Destruction of skin growth, 1-14 growths | 23 | $1,426 | $62 |
| New patient visit (30+ min) | 25 | $1,359 | $54 |
| Biopsy of related skin growth, first growth | 33 | $912 | $26 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $806 | $45 |
| Punch biopsy, first skin growth | 16 | $526 | $33 |
| Destruction of precancer skin growth, 2-14 growths | 64 | $448 | $2 |
| Injection into skin growth, 1-7 growths | 12 | $423 | $22 |
| New patient visit (15+ min) | 12 | $374 | $31 |
2019: 8 services
| Return visit (30+ min) | 225 | $16,440 | $61 |
| Short return visit (20+ min) | 132 | $6,428 | $37 |
| Destruction of precancer skin growth, 1 growth | 93 | $5,187 | $43 |
| New patient visit (30+ min) | 37 | $2,214 | $60 |
| Destruction of skin growth, 1-14 growths | 24 | $1,739 | $62 |
| Biopsy of related skin growth, first growth | 43 | $1,055 | $25 |
| Destruction of precancer skin growth, 2-14 growths | 63 | $555 | $2 |
| Punch biopsy, first skin growth | 13 | $526 | $40 |
2018: 8 services
| Return visit (30+ min) | 203 | $14,814 | $58 |
| Short return visit (20+ min) | 133 | $7,976 | $40 |
| Destruction of precancer skin growth, 1 growth | 109 | $6,178 | $41 |
| Biopsy of single growth of skin and/or tissue | 55 | $1,837 | $31 |
| New patient visit (30+ min) | 30 | $1,778 | $59 |
| Destruction of skin growth, 1-14 growths | 24 | $1,521 | $58 |
| Injection into skin growth, 1-7 growths | 13 | $745 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 78 | $642 | $2 |
2017: 8 services
| Return visit (30+ min) | 185 | $13,441 | $57 |
| Short return visit (20+ min) | 150 | $8,488 | $38 |
| Destruction of precancer skin growth, 1 growth | 107 | $6,277 | $41 |
| New patient visit (30+ min) | 39 | $2,442 | $63 |
| Biopsy of single growth of skin and/or tissue | 69 | $2,291 | $30 |
| Destruction of skin growth, 1-14 growths | 31 | $2,233 | $54 |
| Destruction of precancer skin growth, 2-14 growths | 74 | $792 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $430 | $21 |
2016: 7 services
| Return visit (30+ min) | 156 | $9,656 | $54 |
| Short return visit (20+ min) | 104 | $5,026 | $35 |
| Destruction of precancer skin growth, 1 growth | 102 | $4,910 | $37 |
| Biopsy of single growth of skin and/or tissue | 52 | $1,680 | $31 |
| New patient visit (30+ min) | 22 | $1,317 | $60 |
| Destruction of skin growth, 1-14 growths | 17 | $739 | $43 |
| Destruction of precancer skin growth, 2-14 growths | 81 | $580 | $2 |
2015: 8 services
| Return visit (30+ min) | 179 | $11,765 | $57 |
| Short return visit (20+ min) | 139 | $7,268 | $37 |
| Destruction of precancer skin growth, 1 growth | 127 | $6,758 | $39 |
| New patient visit (30+ min) | 41 | $2,506 | $61 |
| Biopsy of single growth of skin and/or tissue | 75 | $2,411 | $31 |
| Destruction of skin growth, 1-14 growths | 21 | $1,284 | $51 |
| Destruction of precancer skin growth, 2-14 growths | 92 | $676 | $2 |
| Short return visit | 19 | $419 | $19 |
2014: 10 services
| Return visit (30+ min) | 116 | $7,548 | $56 |
| Short return visit (20+ min) | 130 | $6,633 | $38 |
| Destruction of precancer skin growth, 1 growth | 120 | $6,484 | $41 |
| New patient visit (30+ min) | 67 | $3,680 | $55 |
| Biopsy of single growth of skin and/or tissue | 90 | $2,995 | $29 |
| Short return visit | 54 | $1,322 | $19 |
| Destruction of skin growth, 1-14 growths | 17 | $1,101 | $55 |
| Injection into skin growth, 1-7 growths | 14 | $999 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 88 | $691 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 23 | $512 | $20 |
2013: 9 services
| Return visit (30+ min) | 83 | $4,682 | $52 |
| Short return visit (20+ min) | 103 | $4,203 | $32 |
| Destruction of precancer skin growth, 1 growth | 76 | $4,174 | $40 |
| New patient visit (30+ min) | 36 | $1,834 | $51 |
| Biopsy of single growth of skin and/or tissue | 56 | $1,717 | $28 |
| Destruction of precancer skin growth, 2-14 growths | 50 | $839 | $3 |
| Destruction of skin growth, 1-14 growths | 12 | $634 | $53 |
| Short return visit | 25 | $482 | $18 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $309 | $21 |
Medicaid work
$3,724 in 2024
Medicaid paid $3,724 for 56 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OFF/OP EST MAY X REQ PHY/QHP | 12 | $1,948 |
| Return visit (30+ min) | 44 | $1,776 |
| 2024 | 56 | 2 | 18 | $3,724 |
| 2023 | 66 | 1 | 20 | $2,855 |
| 2022 | 88 | 1 | 18 | $3,425 |
| 2021 | 82 | 1 | 17 | $3,023 |
| 2020 | 32 | 2 | 16 | $1,051 |
| 2018 | 13 | 1 | 12 | $265 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 66 | $2,855 |
2022
| Return visit (30+ min) | 88 | $3,425 |
2021
| Return visit (30+ min) | 82 | $3,023 |
2020
| Return visit (30+ min) | 13 | $609 |
| Short return visit (20+ min) | 19 | $442 |
2018
| Short return visit (20+ min) | 13 | $265 |
Drugs they prescribed that Part D paid
$133,039
Pharmacies billed $133,039 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 868) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
821 generic and 47 brand-name prescriptions · $133,039 in drug cost · 20 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tacrolimus | 22 | $2,985 | $136 |
| Minoxidil | 197 | $1,703 | $9 |
| Dutasteride | 54 | $1,668 | $31 |
| Tretinoin | 24 | $1,439 | $60 |
| Fluorouracil | 22 | $1,419 | $64 |
See all 20 drugs
| Tacrolimus | 22 | $2,985 | $136 |
| Minoxidil | 197 | $1,703 | $9 |
| Dutasteride | 54 | $1,668 | $31 |
| Tretinoin | 24 | $1,439 | $60 |
| Fluorouracil | 22 | $1,419 | $64 |
| Fluocinonide | 28 | $1,410 | $50 |
| Hydroxychloroquine Sulfate | 65 | $1,138 | $18 |
| Desonide | 23 | $1,130 | $49 |
| Betamethasone Diprop Augmented | 22 | $1,093 | $50 |
| Econazole Nitrate | 21 | $1,065 | $51 |
| Finasteride | 93 | $971 | $10 |
| Betamethasone Dipropionate | 14 | $951 | $68 |
| Clobetasol Propionate | 16 | $818 | $51 |
| Ketoconazole | 56 | $734 | $13 |
| Metronidazole | 16 | $658 | $41 |
| Doxycycline Monohydrate | 16 | $591 | $37 |
| Mometasone Furoate | 13 | $364 | $28 |
| Fluocinolone Acetonide | 13 | $343 | $26 |
| Triamcinolone Acetonide | 33 | $316 | $10 |
| Nystatin | 12 | $152 | $13 |
Year by year
| 2024 | 868 | 242 | 0% (0) | 5% | $133,039 |
| 2023 | 797 | 230 | 0% (0) | None | $203,818 |
| 2022 | 593 | 203 | 0% (0) | 8% | $39,813 |
| 2021 | 449 | 167 | 0% (0) | 16% | $28,270 |
| 2020 | 325 | 128 | 0% (0) | 11% | $16,104 |
| 2019 | 314 | 131 | 0% (0) | 21% | $18,991 |
| 2018 | 321 | 130 | 0% (0) | 29% | $24,716 |
| 2017 | 233 | 105 | 0% (0) | 27% | $20,878 |
| 2016 | 296 | 110 | 0% (0) | 22% | $34,200 |
| 2015 | 351 | 124 | 0% (0) | 23% | $42,768 |
| 2014 | 276 | 97 | 0% (0) | None | $24,961 |
| 2013 | 176 | 74 | 0% (0) | 13% | $15,241 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Dupixent | 15 | $56,378 | $3,759 |
| Tacrolimus | 19 | $4,691 | $247 |
| Clobetasol Propionate | 24 | $2,230 | $93 |
| Tretinoin | 22 | $1,845 | $84 |
| Fluorouracil | 17 | $1,685 | $99 |
| Desonide | 18 | $1,528 | $85 |
| Betamethasone Diprop Augmented | 22 | $1,387 | $63 |
| Clindamycin Phosphate | 18 | $1,376 | $76 |
| Hydroxychloroquine Sulfate | 42 | $1,352 | $32 |
| Fluocinonide | 26 | $1,238 | $48 |
| Dutasteride | 39 | $1,216 | $31 |
| Finasteride | 73 | $1,159 | $16 |
| Minoxidil | 147 | $992 | $7 |
| Ketoconazole | 67 | $882 | $13 |
| Fluocinolone Acetonide | 16 | $841 | $53 |
| Fluocinolone Acetonide | 19 | $834 | $44 |
| Doxycycline Monohydrate | 12 | $622 | $52 |
| Mometasone Furoate | 18 | $455 | $25 |
| Triamcinolone Acetonide | 49 | $406 | $8 |
| Econazole Nitrate | 13 | $335 | $26 |
2022: 18 drugs
| Tacrolimus | 13 | $3,190 | $245 |
| Fluocinonide | 55 | $2,297 | $42 |
| Fluorouracil | 21 | $1,958 | $93 |
| Betamethasone Diprop Augmented | 18 | $1,772 | $98 |
| Clindamycin Phosphate | 20 | $1,377 | $69 |
| Fluocinolone Acetonide | 11 | $1,063 | $97 |
| Ketoconazole | 77 | $1,040 | $14 |
| Metronidazole | 12 | $952 | $79 |
| Desonide | 19 | $944 | $50 |
| Econazole Nitrate | 11 | $912 | $83 |
| Hydroxychloroquine Sulfate | 14 | $852 | $61 |
| Fluocinolone Acetonide | 16 | $823 | $51 |
| Finasteride | 51 | $779 | $15 |
| Clobetasol Propionate | 14 | $614 | $44 |
| Triamcinolone Acetonide | 45 | $576 | $13 |
| Valacyclovir | 14 | $498 | $36 |
| Spironolactone | 12 | $257 | $21 |
| Minoxidil | 60 | $192 | $3 |
2021: 14 drugs
| Fluocinonide | 55 | $2,377 | $43 |
| Fluorouracil | 25 | $2,377 | $95 |
| Betamethasone Diprop Augmented | 20 | $1,827 | $91 |
| Clindamycin Phosphate | 19 | $1,720 | $91 |
| Econazole Nitrate | 12 | $1,452 | $121 |
| Metronidazole | 14 | $1,036 | $74 |
| Ketoconazole | 69 | $1,036 | $15 |
| Desonide | 18 | $877 | $49 |
| Clobetasol Propionate | 15 | $748 | $50 |
| Hydroxychloroquine Sulfate | 18 | $618 | $34 |
| Doxycycline Monohydrate | 11 | $298 | $27 |
| Triamcinolone Acetonide | 24 | $250 | $10 |
| Spironolactone | 11 | $224 | $20 |
| Finasteride | 14 | $143 | $10 |
2020: 11 drugs
| Fluocinonide | 39 | $2,192 | $56 |
| Fluorouracil | 16 | $1,403 | $88 |
| Fluocinolone Acetonide | 14 | $1,350 | $96 |
| Betamethasone Diprop Augmented | 11 | $1,245 | $113 |
| Clobetasol Propionate | 19 | $1,187 | $62 |
| Doxycycline Hyclate | 21 | $1,080 | $51 |
| Metronidazole | 14 | $1,030 | $74 |
| Ketoconazole | 47 | $954 | $20 |
| Methotrexate | 16 | $622 | $39 |
| Triamcinolone Acetonide | 34 | $406 | $12 |
| Valacyclovir | 11 | $277 | $25 |
2019: 9 drugs
| Metronidazole | 26 | $2,251 | $87 |
| Fluorouracil | 20 | $2,218 | $111 |
| Fluocinolone Acetonide | 22 | $2,108 | $96 |
| Tretinoin | 14 | $1,882 | $134 |
| Fluocinonide | 26 | $1,503 | $58 |
| Ketoconazole | 61 | $1,099 | $18 |
| Clobetasol Propionate | 13 | $941 | $72 |
| Desonide | 11 | $744 | $68 |
| Triamcinolone Acetonide | 29 | $259 | $9 |
2018: 10 drugs
| Clobetasol Propionate | 14 | $3,137 | $224 |
| Tretinoin | 23 | $3,098 | $135 |
| Fluorouracil | 21 | $2,813 | $134 |
| Fluocinonide | 22 | $1,463 | $67 |
| Betamethasone Dipropionate | 13 | $1,284 | $99 |
| Ketoconazole | 37 | $1,019 | $28 |
| Econazole Nitrate | 13 | $775 | $60 |
| Doxycycline Hyclate | 12 | $729 | $61 |
| Triamcinolone Acetonide | 31 | $358 | $12 |
| Valacyclovir | 12 | $172 | $14 |
2017: 6 drugs
| Fluorouracil | 15 | $1,985 | $132 |
| Metronidazole | 14 | $1,702 | $122 |
| Fluocinonide | 22 | $1,437 | $65 |
| Ketoconazole | 18 | $284 | $16 |
| Triamcinolone Acetonide | 21 | $256 | $12 |
| Valacyclovir | 14 | $176 | $13 |
2016: 11 drugs
| Clobetasol Propionate | 38 | $10,616 | $279 |
| Hydroxychloroquine Sulfate | 12 | $2,224 | $185 |
| Fluocinonide | 26 | $2,129 | $82 |
| Desonide | 17 | $2,125 | $125 |
| Clindamycin Phosphate | 27 | $1,838 | $68 |
| Tretinoin | 11 | $1,741 | $158 |
| Econazole Nitrate | 11 | $882 | $80 |
| Ammonium Lactate | 13 | $445 | $34 |
| Ketoconazole | 30 | $427 | $14 |
| Mometasone Furoate | 13 | $366 | $28 |
| Triamcinolone Acetonide | 22 | $318 | $14 |
2015: 12 drugs
| Clobetasol Propionate | 31 | $7,801 | $252 |
| Desonide | 31 | $4,222 | $136 |
| Econazole Nitrate | 18 | $4,190 | $233 |
| Fluocinonide | 34 | $2,735 | $80 |
| Tretinoin | 17 | $2,440 | $144 |
| Fluocinolone Acetonide | 12 | $1,858 | $155 |
| Fluorouracil | 12 | $1,690 | $141 |
| Metronidazole | 11 | $1,447 | $132 |
| Clindamycin Phosphate | 18 | $1,205 | $67 |
| Ketoconazole | 47 | $793 | $17 |
| Ammonium Lactate | 15 | $379 | $25 |
| Triamcinolone Acetonide | 19 | $249 | $13 |
2014: 7 drugs
| Desonide | 26 | $3,571 | $137 |
| Fluocinonide | 37 | $2,651 | $72 |
| Doxycycline Hyclate | 11 | $1,792 | $163 |
| Clobetasol Propionate | 29 | $1,351 | $47 |
| Ketoconazole | 32 | $537 | $17 |
| Ammonium Lactate | 13 | $307 | $24 |
| Triamcinolone Acetonide | 19 | $305 | $16 |
2013: 6 drugs
| Desonide | 20 | $1,404 | $70 |
| Fluocinonide | 24 | $1,294 | $54 |
| Clobetasol Propionate | 24 | $602 | $25 |
| Ketoconazole | 23 | $402 | $17 |
| Triamcinolone Acetonide | 15 | $288 | $19 |
| Ammonium Lactate | 11 | $206 | $19 |
Money from drug and device companies
$949 in 2025
| 2025 | 2 | 2 | $813 | $949 |
| 2020 | 1 | 1 | $800 | $800 |
| 2019 | 1 | 1 | None | $249 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | None | $813 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $137 | 1 payment
|
See all 2 published payments
| Sun Pharmaceutical Industries | Meals · 2025-07-12 | Ilumya | $137 |
| Abbvie | Consulting · 2025-06-26 | None | $813 |
See earlier years (2020, 2019)
2020: $800
| Pfizer | None | $800 | 1 payment
|
2019: $249
| Intuitive Surgical | Da Vinci Surgical System | $249 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ABBVIE INC. · A Study To Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-Aa) · 2024 | Their institution | $13,007 |
Professional record
- NPI
- 1376739268
- Licence
- CA A96417, MA 245761California A96417: Cancelled
- Trained
- Stanford University School of Medicine, 2005
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 221 Longwood Ave, Boston, MA, 02115
- NPI first listed
- 2007-09-24
- NPI last updated
- 2012-02-08
This is when the NPI record was last certified, not a medical board exam.